Mylotarg (gemtuzumab ozogamicin)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

PDL, Pfizer, UCB

Drug class:

DNA replication inhibitor, CD33-targeted antibody-drug conjugate

Related drugs:

‹

›

CD33 positive	Acute Myelogenous Leukemia	CD33 positive	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A1 - Approval gemtuzumab ozogamicin Sensitive : A1	gemtuzumab ozogamicin Sensitive: A1 - Approval gemtuzumab ozogamicin Sensitive : A1
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
CBFB-MYH11 fusion	Acute Myelogenous Leukemia	CBFB-MYH11 fusion	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
No biomarker	Acute Promyelocytic Leukemia	No biomarker	Acute Promyelocytic Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
WT1 underexpression	Acute Myelogenous Leukemia	WT1 underexpression	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3
CD33 positive	Acute Myelogenous Leukemia	CD33 positive	Acute Myelogenous Leukemia	talazoparib + gemtuzumab ozogamicin Sensitive: C3 – Early Trials talazoparib + gemtuzumab ozogamicin Sensitive : C3	talazoparib + gemtuzumab ozogamicin Sensitive: C3 – Early Trials talazoparib + gemtuzumab ozogamicin Sensitive : C3
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3
KRAS mutation	Acute Myelogenous Leukemia	KRAS mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3	gemtuzumab ozogamicin Sensitive: C3 – Early Trials gemtuzumab ozogamicin Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Resistant: C3 – Early Trials gemtuzumab ozogamicin Resistant : C3	gemtuzumab ozogamicin Resistant: C3 – Early Trials gemtuzumab ozogamicin Resistant : C3
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Resistant: C3 – Early Trials gemtuzumab ozogamicin Resistant : C3	gemtuzumab ozogamicin Resistant: C3 – Early Trials gemtuzumab ozogamicin Resistant : C3
ASXL1 mutation	Acute Myelogenous Leukemia	ASXL1 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Resistant: C3 – Early Trials gemtuzumab ozogamicin Resistant : C3	gemtuzumab ozogamicin Resistant: C3 – Early Trials gemtuzumab ozogamicin Resistant : C3
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Resistant: C3 – Early Trials gemtuzumab ozogamicin Resistant : C3	gemtuzumab ozogamicin Resistant: C3 – Early Trials gemtuzumab ozogamicin Resistant : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3
DDB2 rs830083	Acute Myelogenous Leukemia	DDB2 rs830083	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Resistant: D – Preclinical gemtuzumab ozogamicin Resistant : D	gemtuzumab ozogamicin Resistant: D – Preclinical gemtuzumab ozogamicin Resistant : D

Mylotarg (gemtuzumab ozogamicin)

Associations
(24)

Associations
(24)

Mylotarg (gemtuzumab ozogamicin)

Associations(24)

Associations(24)

Associations
(24)

Associations
(24)